PNC-27 vs LL-37 — Peptide Comparison

At a Glance

Quickcomparison

Dose Range

PNC-27

1–2 mg

LL-37

0.5–1.6 mg/mL (topical)

Frequency

Once daily

Administration

Subcutaneous injection

Topical application (wound healing)

Cycle Length

4-6 weeks

12+ weeks

Onset Speed

Rapid (hours to days)

Moderate (1-2 weeks)

Evidence Level

Strong preclinical (extensive animal studies)

Moderate human trials (Phase 1-2)

Efficacy

Benefitratings

Cancer Cell Selectivity

Rapid Action

Broad Spectrum

Wound Healing

Fighting Infections

Immune Boost

Technical Data

Compoundspecifications

Molecular Formula

C188H293N53O44S

Molecular Weight

4031.73 g/mol

Half-Life

2-4 hours (estimated from preclinical data)

Bioavailability

High when injected subcutaneously

CAS Number

1159861-00-3

C205H340N60O53

4,493.26 Da

Short systemic half-life (minutes) due to protease susceptibility; local tissue persistence at wound sites is longer due to binding to extracellular matrix components and lipid membranes

Topical application achieves high local wound-bed concentrations; systemic bioavailability limited by rapid proteolytic degradation and serum protein binding; not intended for oral delivery

154947-66-7

Protocols

Dosingtiers

starting

0.5 mg/mL gel

Twice weekly

4 weeks

Lowest dose in the LL-37 (ropocamptide) Phase I/IIa venous leg-ulcer trial and the most effective: ~6-fold faster healing and ~68% ulcer-area reduction vs placebo, applied to the wound twice weekly [4].

standard

1.6 mg/mL gel

Mid dose in the same trial; ~3-fold improvement and ~50% area reduction vs placebo. The highest tested concentration (3.2 mg/mL) showed no benefit over placebo, so dose escalation above this is not supported [4].

Applications

Bestsuited for

Solid Tumor Research

PNC-27 has shown remarkable results against solid tumors in lab studies. It's been tested against breast, pancreatic, colon, and ovarian cancer cells—and in each case, it killed the cancer cells while the healthy cells next to them stayed perfectly fine. That's the holy grail of cancer research.

Leukemia and Blood Cancer Studies

In studies on acute myeloid leukemia (AML), PNC-27 wiped out cancer cells within just 4 hours. It works on several types of leukemia cells (U937, OCI-AML3, HL-60) by targeting a protein that only shows up on cancer cell surfaces. Normal blood cells? Completely unharmed.

Cancer Stem Cell Targeting

Here's where PNC-27 gets really interesting: it can kill cancer stem cells. These are the sneaky cells that often survive chemo and cause cancer to come back. PNC-27 has shown it can destroy CD44+ colon cancer stem cells, which is a big deal for preventing recurrence.

Drug-Resistant Cancer Research

When cancers stop responding to regular chemotherapy, researchers need new approaches. PNC-27 works through a completely different mechanism than traditional chemo drugs, so it may be effective against cancers that have become resistant to other treatments.

Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers

LL-37 is particularly well-suited for individuals focused on treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)

LL-37 is particularly well-suited for individuals focused on immune defense against antibiotic-resistant bacterial infections (mrsa, pseudomonas). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Anti-biofilm strategies for chronic wound infections and medical device-associated infections

LL-37 is particularly well-suited for individuals focused on anti-biofilm strategies for chronic wound infections and medical device-associated infections. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Boosting innate immune defense in immunocompromised or aging individuals

LL-37 is particularly well-suited for individuals focused on boosting innate immune defense in immunocompromised or aging individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Injection site redness

Mild fatigue

Localized warmth or tenderness

Uncommon

Headache

Low-grade fever

Serious

Allergic reaction

Local site irritation

Transient stinging or burning

Mild perilesional erythema

Increased wound exudate

Allergic contact reaction

Hemolytic activity at systemic concentrations

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Here's the really cool thing about PNC-27: in all the lab and animal studies so far, it ONLY attacks cancer cells. Normal, healthy cells are completely ignored because they don't have the protein (HDM-2) on their surface that PNC-27 targets. Animal studies using doses up to 40 mg/kg showed tumors shrinking or disappearing with zero damage to normal tissues. That said, it hasn't been tested in human clinical trials yet, so we're still learning.

Contraindications

xPregnancy or planning to become pregnant

xCurrently breastfeeding

xKnown allergy to peptide components

xSevere immune system disorders without specialist guidance

LL-37 is an endogenous cathelicidin antimicrobial peptide naturally produced by immune cells and epithelial tissues, conferring inherent biocompatibility and low toxicity at physiological concentrations. Synthetic LL-37 shows excellent safety in in vitro immune assays and animal models with no hepatotoxicity, nephrotoxicity, or genotoxicity at relevant doses. At elevated concentrations, the cationic amphipathic structure can cause hemolysis and cell membrane damage, but therapeutic doses are far below these thresholds. Injection site reactions are minimal in research applications.

xKnown hypersensitivity to cathelicidin peptides or formulation components

xActive hemolytic conditions — LL-37 demonstrates concentration-dependent hemolytic activity

xPregnancy and breastfeeding — insufficient reproductive safety data from clinical trials

xSevere renal impairment — peptide clearance may be altered

Decision Guide

Which isright for you?

Choose PNC-27 if...

Cancer research protocols

Oncology support research

Targeting treatment-resistant cancers

Cancer stem cell research

Choose LL-37 if...

Treatment of chronic non-healing wounds including venous leg ulcers and diabetic ulcers

Immune defense against antibiotic-resistant bacterial infections (MRSA, Pseudomonas)

Anti-biofilm strategies for chronic wound infections and medical device-associated infections

Boosting innate immune defense in immunocompromised or aging individuals